Seagen Inc (SGEN)
151.11
+1.02 +0.68%
NASDAQ
Feb 26, 20:00
USD
View All Key Stats
Key Stats
Income Statement | |
Revenue (TTM) | 2.176B |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (TTM) | 3.30 |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Net Income (TTM) | 613.67M |
Profitability | |
Gross Profit Margin (Quarterly) | 89.73% |
Profit Margin (Quarterly) | 27.79% |
Dividend | |
Dividend Yield (Forward) | Upgrade |
Dividend Yield | 0.00% |
Price and Valuation | |
Market Cap | 27.38B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
PS Ratio | 12.40 |
PE Ratio | 45.79 |
Price to Book Value | 7.848 |
Other | |
Beta (5Y) | Upgrade |
Debt to Equity Ratio | 0.00 |
Free Cash Flow (Quarterly) | 172.63M |
Return on Equity | Upgrade |
View All SGEN News
News
-
WireHeadlineTime (ET)
-
Yahoo02/27 09:23
-
Yahoo02/24 08:00
-
MT Newswires02/18 12:27
-
PR Newswire02/18 08:00
-
Yahoo02/18 08:00
-
MT Newswires02/16 07:53
-
Yahoo02/15 05:41
-
SA Breaking News02/12 15:15
-
PR Newswire02/12 14:15
-
Yahoo02/12 14:15
-
PR Newswire02/12 14:15
-
Yahoo02/12 14:15
-
MT Newswires02/12 12:50
-
MT Newswires02/12 11:45
-
MT Newswires02/12 10:44
-
MT Newswires02/12 10:43
-
MT Newswires02/12 10:41
-
MT Newswires02/12 10:40
-
Yahoo02/12 10:28
-
SA Breaking News02/12 07:45
View All Events
Events
Date | Type | Description |
---|---|---|
04/30/2021 | Earnings | Seattle Genetics Inc First Quarter Earnings Results for 2021 |
04/30/2021 | Misc | Seattle Genetics Inc First Quarter Earnings Conference Call for 2021 |
02/11/2021 | Earnings | Seagen Inc Fourth Quarter Earnings Result for 2020 |
02/11/2021 16:30 EST | Misc | Seagen Inc Fourth Quarter Earnings Conference Call for 2020 |
10/29/2020 16:30 EDT | Misc | Seagen Inc Third Quarter Earnings Conference Call for 2020 |
10/29/2020 | Earnings | Seagen Inc Third Quarter Earnings Result for 2020 |
07/30/2020 16:30 EDT | Misc | Seattle Genetics Inc Second Quarter Earnings Conference Call for 2020 |
07/30/2020 | Earnings | Seattle Genetics Inc Second Quarter Earnings Result for 2020 |
05/15/2020 11:00 PDT | Misc | Seattle Genetics Inc Annual General Meeting for 2019 |
04/30/2020 16:30 EDT | Misc | Seattle Genetics Inc First Quarter Earnings Conference Call for 2020 |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: https://www.seagen.com
- Investor Relations URL: http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-IRHome
- HQ State/Province: Washington
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Mid Cap/Growth
- Next Earnings Release: Apr. 30, 2021
- Last Earnings Release: Feb. 11, 2021
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Seagen Inc is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. Other approved products include Padcev (bladder cancer) and Tukysa (breast cancer). The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.
Analyst Coverage
Consensus Recommendations | |
Buy Recommendations | Upgrade |
Outperform Recommendations | Upgrade |
Hold Recommendations | Upgrade |
Underperform Recommendations | Upgrade |
Sell Recommendations | Upgrade |
Consensus Recommendation | Upgrade |
Consensus Rating | Upgrade |
Target Price | |
Price | 151.11 |
Price Target | Upgrade |
Price Target Upside (Daily) | Upgrade |
Top Fund Holders
Symbol | Name | Weighting |
---|---|---|
HQL | Tekla Life Sciences Investors | 4.64% |
HQH | Tekla Healthcare Investors | 4.13% |
BBH | VanEck Vectors Biotech ETF | 3.53% |
POAGX | PRIMECAP Odyssey Aggressive Growth | 2.83% |
BMEZ | BlackRock Health Sciences Trust II | 2.74% |
IBB | iShares Nasdaq Biotechnology ETF | 2.22% |
POGRX | PRIMECAP Odyssey Growth | 2.14% |
BME | BlackRock Health Sciences | 2.11% |
SHISX | BlackRock Health Sciences Opps Svc | 1.97% |
VHCOX | Vanguard Capital Opportunity Inv | 1.86% |
JLGZX | JPMorgan Large Cap Growth R2 | 1.80% |
THISX | T. Rowe Price Health Sciences I | 1.29% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- SGEN Tweets Stocktwits
Advertisement